BTIG analyst Sean Lavin raised his price target on Exact Sciences to $110 and kept his Buy rating after its Q4 earnings beat and better than expected FY19 guidance. The analyst warns that the company's high multiple and rising expenses could become an issue for the stock if the bull market turns, but thus far remains positive on Exact Sciences' revenue growth exceeding that of costs. Lavin also notes the company's "more definitive timeframe for expansion into the age 45-49 cohort" for its Cologuard, helped by the " lack of a comprehensive trial to earn FDA approval".